Detecting symptom exaggeration in combat veterans using the MMPI-2 symptom validity scales: a mixed group validation.
Detecting symptom exaggeration in combat veterans using the MMPI-2 symptom validity scales: a mixed group validation.
复制标题
使用 MMPI-2 症状有效性量表检测退伍军人的症状夸大：混合组验证。
作者：
D. Tolin;M. Steenkamp;B. Marx;B. Litz
尽管明尼苏达多相人格量表-2 （MMPI-2； J. N. Butcher， W. G. Dahlstrom， J. R. Graham， A. Tellegen, & B. Kaemmer, 1989）的效度量表在标准组验证（CGV）研究中被证明在检测症状夸大方面是有用的，通常比较指示的伪装者和已知的患者群体，但在评估经历创伤后应激障碍（PTSD）检查的退伍军人时，这些量表的应用一直存在问题。采用混合组验证（MGV）来确定MMPI-2夸大量表在寻求补偿（CS）和非寻求补偿（NCS）退伍军人中的效果。与CGV不同的是，MGV允许在每一组中混合夸张和不夸张的个体，不需要知道任何个体的夸张和不夸张状态，并且可以根据不同的基本率估计进行调整。对377名男性退伍军人的MMPI-2反应进行了比较。MGV使用从文献中提取的4组基本率估计来计算。在大多数基本率估计下，效度量表通常表现良好（足够的灵敏度、特异性和效率），并且大多数产生的截止分数显示足够的症状夸大检测，无论基本率假设如何。这些结果支持在退伍军人群体中使用MMPI-2效度量表进行PTSD评估，即使在不同的症状夸大基础率下也是如此。
Although validity scales of the Minnesota Multiphasic Personality Inventory-2 (MMPI-2; J. N. Butcher, W. G. Dahlstrom, J. R. Graham, A. Tellegen, & B. Kaemmer, 1989) have proven useful in the detection of symptom exaggeration in criterion-group validation (CGV) studies, usually comparing instructed feigners with known patient groups, the application of these scales has been problematic when assessing combat veterans undergoing posttraumatic stress disorder (PTSD) examinations. Mixed group validation (MGV) was employed to determine the efficacy of MMPI-2 exaggeration scales in compensation-seeking (CS) and noncompensation-seeking (NCS) veterans. Unlike CGV, MGV allows for a mix of exaggerating and nonexaggerating individuals in each group, does not require that the exaggeration versus nonexaggerating status of any individual be known, and can be adjusted for different base-rate estimates. MMPI-2 responses of 377 male veterans were examined according to CS versus NCS status. MGV was calculated using 4 sets of base-rate estimates drawn from the literature. The validity scales generally performed well (adequate sensitivity, specificity, and efficiency) under most base-rate estimations, and most produced cutoff scores that showed adequate detection of symptom exaggeration, regardless of base-rate assumptions. These results support the use of MMPI-2 validity scales for PTSD evaluations in veteran populations, even under varying base rates of symptom exaggeration.